Is Biontech SE halal to invest in?

As of August 2026, Biontech SE BNTX.VI is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.

Is Biontech SE a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Biontech SE using these criteria to determine its compliance status.

Can Muslims buy shares of Biontech SE?

Muslim investors may consider investing in Biontech SE if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Biontech SE classified as NOT HALAL?

Musaffa determines the Shariah status of Biontech SE by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Biontech SE updated?

The Shariah compliance status of Biontech SE may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Biontech SE become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Biontech SE?

You can check the latest Shariah compliance status of Biontech SE on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

Biontech SE BNTX.VI

Last Updated: Aug 14, 12:00 AM·WBAG

BNTX.VI Shariah Compliance

Screening Methodology: AAOIFI

As of August 2026, Biontech SE is classified as not halal.

NOT HALAL

Report Source: undefined Quarter Report

Biontech SE. Stock Analysis BNTX.VI

Austria Health Care Large Cap

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. The firm focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The firm is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. The company also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.